RecruitingPhase 2Phase 3NCT05516212

Caffeine Kinetics and CrossFit®-Specific Performance

The Effect of Caffeine and Paraxantine Kinetics on Exercise Performance and Psychophysical State in Athletes After Ingestion of Mono- or Multi-ingredient Caffeine-containing Supplements


Sponsor

Poznan University of Physical Education

Enrollment

25 participants

Start Date

Jun 29, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The study aims at assessing the relation between caffeine (CAF) and paraxanthine (PAX) kinetics after acute ingestion of caffeine (3 mg/kg body mass) in the form or mono- or multi-ingredient preparations and CrossFit®-specific performance or selected indicators of psychophysiological state. Blood indicators of muscle damage/recovery, acid-base balance and electrolytes levels will be evaluated. The impact of genetic variations in the polymorphisms rs5751876 in ADORA2A gene and rs762551 in CYP1A2 on CAF/PAX kinetics will be considered.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study examines how caffeine is processed in the body (pharmacokinetics) and how it affects performance in CrossFit and high-intensity functional training (HIFT). It aims to help athletes understand the optimal caffeine dose and timing for peak performance. You may be eligible if... - You are a male between 18 and 40 years old - You have at least 5 years of sports training experience and at least 2 years in high-intensity functional training - You train at least 3 sessions per week - You participate in CrossFit competitions at least once a year - You have medical clearance to practice sports You may NOT be eligible if... - You have a current injury or health condition preventing participation - You feel generally unwell - You are unwilling to follow the study protocol - You smoke or use tobacco - You had an infectious disease in the past 4 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTCAFMONO supplementation

CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF. CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND

DIETARY_SUPPLEMENTCAFMIPS_1 supplementation

CAFMIPS\_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF. CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND

DIETARY_SUPPLEMENTCAFMIPS_2 supplementation

CAFMIPS\_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF. CAFMIPS\_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY.

DIETARY_SUPPLEMENTPlacebo treatment

Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.


Locations(1)

Department of Sports Dietetics, Poznan University of Physical Education

Poznan, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05516212


Related Trials